News
AMGN
262.75
-0.50%
-1.32
See Which Of The Latest 13F Filers Holds Amgen
NASDAQ · 21h ago
Amgen Is Maintained at Neutral by UBS
Dow Jones · 22h ago
Analyst Holds on Amgen’s Tezspire amid COPD Trial Uncertainties and Pending Competitor Comparisons
Leerink Partners analyst David Risinger has maintained their neutral stance on AMGN stock. The analyst has given the stock a Hold rating. Risinger is concerned about the recent clinical trial results for Amgen’s Tezspire in treating COPD. The initial data showed promise in a subgroup of patients with moderate to severe COPD exacerbations.
TipRanks · 1d ago
Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights
NASDAQ · 1d ago
AMGEN INC SAYS CEO ROBERT A. BRADWAY'S 2023 TOTAL COMPENSATION WAS $22.6 MLN VS $21.4 MLN IN 2022 – SEC FILING
Reuters · 1d ago
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Amgen provides update on results of the Phase 2a trial for Tezspire in chronic obstructive pulmonary disease. Tezepelumab numerically reduced the annualized rate of moderate or severe COPD exacerbations versus placebo by 17%. The reduction was not statistically significant.
Benzinga · 1d ago
Analysts See 11% Upside For The Holdings of IWL
NASDAQ · 1d ago
AMGEN INC <AMGN.O>: UBS CUTS TARGET PRICE TO $284 FROM $314
Reuters · 1d ago
AMGN Factor-Based Stock Analysis
NASDAQ · 1d ago
CVS favors Humira copycats hurting AbbVie’s market share: Evercore
Healthcare CVS favors Humira copycats hurting AbbVie’s market share: Evercore ISI. Humira biosimilars are slowly gaining market share after CVS Health changed its formularies to drop coverage for the branded version from April 1.
Seeking Alpha · 1d ago
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Price target for Amgen Inc. Slashed from $370 to $360. Morgan Stanley raised the price target for Antero Resources Corporation. Urban Outfitters, Inc. Shares fell 0.5% to close at $38.02 on Tuesday. The price target was cut for Unity Biotechnology, Inc.'s shares.
Benzinga · 1d ago
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
FDA approval is the number one needle mover for drug stocks. FDA approval for a drug or treatment can bring years of steady, high-margin revenue to a company. Three companies are awaiting key FDA decisions over the next couple of months. Merck & Co, Amgen and Aquestive Therapeutics are among the companies awaiting key decisions.
Investorplace · 1d ago
Can This High-Yield Dividend Stock Keep Beating the S&P 500?
Amgen's shares have come under pressure this year, making it a compelling bargain buy. The drugmaker's stock has outperformed the S&P 500 since 2011. Amgen's stock is a high-yield dividend stock that pays a generous 3.39% annualized yield. The biotech's stock price has fallen 8% this year.
The Motley Fool · 1d ago
Amgen Is Maintained at Buy by TD Cowen
Dow Jones · 2d ago
Amgen Price Target Cut to $360.00/Share From $370.00 by TD Cowen
Dow Jones · 2d ago
TD Cowen Maintains Buy on Amgen, Lowers Price Target to $360
Benzinga · 2d ago
Buy Rating on Amgen: Tezspire’s Market Potential in COPD Treatment Undervalued
TipRanks · 2d ago
Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever
Three of the best undervalued stocks to buy and hold forever are in the air travel industry. Delta Air Lines and Berkshire Hathaway (BRKA) are among the best companies to buy now. The air travel business is facing a shortage of planes, but the long-term future looks bright for the industry. Amgen is a pharma company that aims to develop lower-risk, less popular drugs.
The Motley Fool · 2d ago
U.S. RESEARCH ROUNDUP-3M, J&J, Nuvalent
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. 3M, J&J and Nuvalent are among the companies. Analysts also raise their targets on Amazon, Tractor Supply, UnitedHealth Group and Amgen. NEW: 3M cuts its target price to $110 from $118; 10X Genomics cuts target price.
Reuters · 2d ago
Barclays Keeps Their Sell Rating on Amgen (AMGN)
TipRanks · 2d ago
More
Webull provides a variety of real-time AMGN stock news. You can receive the latest news about Amgen Inc through multiple platforms. This information may help you make smarter investment decisions.
About AMGN
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.